Drug Coverage In The Pandemic: US Payers Shift Focus From Costs To Access, For Now
Executive Summary
Payer concessions to ensure access to drugs during the COVID-19 outbreak offer a benefit to patients and biopharma. But the costs involved could intensify future efforts to manage drug spending.
You may also be interested in...
CVS Warns Broader Cost Controls Coming As Economic Downturn Collides With Costly New Therapies
CVS Caremark's Lotvin reports increased US payer interest in more comprehensive drug management solutions and that some payers are asking about dropping coverage for drug categories.
COVID-19 Economic Fallout May Delay Cell And Gene Therapy Reimbursement Solutions
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.
Part B Drugs At Home: Medicare Policy Responds To COVID-Driven Access Concerns
Temporary policy may open door to longer term change as Medicare allows reimbursement of at-home administration of non-hospital drugs covered by Part B under a recently-released regulation aiding at encouraging telehealth during the coronavirus outbreak.